Skip to product information
1 of 7

Myo & D-Chiro Inositol

Myo & D-Chiro Inositol

Women's Health Supplement

This formula delivers a clinical 40:1 ratio of Myo-Inositol to D-Chiro-Inositol—the same ratio shown in research to support hormone balance, insulin sensitivity, and ovulatory function. It’s gentle, non-hormonal, and easy to integrate into a daily routine. Whether you're working to regulate your cycle, improve metabolic health, or support fertility, this formula offers clean, targeted support rooted in science and aligned with your goals.

View full details

Myo & D-Chiro Inositol

Women's Health Supplement

Myo-Inositol

Health Benefits & Function

Myo-Inositol is a naturally occurring compound in the B-vitamin family that plays a vital role in cellular signaling and insulin function. In higher doses, it’s been shown to improve ovarian health, support regular menstrual cycles, and enhance metabolic function—particularly in individuals with insulin resistance or PCOS. It’s the most abundant and bioactive form of inositol found in the body.

D-Chiro-Inositol

Health Benefits & Function

D-Chiro-Inositol complements Myo-Inositol by supporting healthy glucose metabolism and insulin signaling. While the body can convert Myo-Inositol into D-Chiro-Inositol, individuals with metabolic imbalances often struggle to maintain this conversion. Including both in the clinically studied 40:1 ratio ensures optimal synergy—especially for supporting ovulation, egg quality, and hormonal balance.

OUR PROMISE Bringing Clean Wellness to You

Vegan-Friendly
Gluten-Free
Non-GMO
Sugar-Free
No Additives or Fillers
Made in USA
cGMP ASI Certified

Key Benefits

  • Ovarial and Hormonal Health
  • Supports Regular Cycles
  • Optimal 40:1 Inositol Ratio

Product Reviews Disclaimer

We do not monitor, moderate or control the content of consumer reviews or comments, but reserve the right to remove what are, in our sole opinion, clearly false or malicious statements, spam or other injurious materials that are brought to our attention, under the terms of Section 230 of the Telecommunications Act. We do not adopt or endorse any such review or comment statements.